Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
Sign Up to like & getrecommendations! Published in 2019 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2019.1649378
Abstract: Abstract Objectives: To compare the efficacy of emicizumab prophylaxis with that of factor VIII (FVIII) prophylaxis in patients with hemophilia A without inhibitors using two approaches: network meta-analyses (NMA) and additional sub-group analyses from the… read more here.
Keywords: hemophilia without; prophylaxis; emicizumab prophylaxis; sub ... See more keywords
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2115777
Abstract: Abstract Background and objective A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors. Methods The model was based on 100 patients from the… read more here.
Keywords: recombinant factor; without inhibitors; cost; emicizumab ... See more keywords